Snapshot from Jul 28, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Regeneron class action over trial failure
Regulatory securities class action

Regeneron class action over trial failure

Analysis based on 7 articles · First reported Jul 16, 2026 · Last updated Jul 27, 2026

Sentiment
-40
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Regeneron's stock price fell significantly upon disclosure of trial issues and failure, erasing billions in market value. The class action may result in financial liability for the company and further negative sentiment among investors.

Pharmaceuticals Biotechnology
Event Summary

A securities class action was filed against Regeneron Pharmaceuticals by Robbins LLP on behalf of investors who purchased REGN stock between August 1, 2025 and May 15, 2026. The lawsuit alleges that Regeneron misled investors about the viability of its Phase 3 Fianlimab-Libtayo study for advanced melanoma, concealing flawed statistical assumptions and the trial's likely failure. On April 29, 2026, Regeneron disclosed a trial modification, causing a 6.2% stock drop. On May 15, 2026, the company announced the trial failed to meet its primary endpoint, leading to a further 9.8% decline. The lead plaintiff deadline is September 14, 2026.

Key Actions
100 Regeneron Pharmaceuticals disclosed trial failure
80 Regeneron Pharmaceuticals announced trial expansion
70 Robbins LLP filed class action Regeneron Pharmaceuticals
Entities Involved
stock
Regeneron Pharmaceuticals
Regeneron is the defendant in the class action; its stock dropped 6.2% and 9.8% on key disclosure dates, and the trial failure damages its pipeline prospects.
Importance 100.0 Sentiment -60.0
priv
Robbins LLP
Robbins LLP is the law firm that filed the class action on behalf of investors, seeking damages and governance reforms.
Importance 30.0 Sentiment 0.0
exch
Nasdaq
Nasdaq is the exchange where Regeneron is listed; the event affects trading of REGN shares.
Importance 10.0 Sentiment 0.0
per
Aaron Dumas, Jr.
Aaron Dumas, Jr. is the attorney at Robbins LLP available for investor inquiries regarding the class action.
Importance 5.0 Sentiment 0.0
per
Brian J. Robbins
Brian J. Robbins is the founding partner of Robbins LLP, quoted in the press releases about the firm's commitment to shareholder rights.
Importance 5.0 Sentiment 0.0
Relationships
Robbins LLP related ↔ Nasdaq
Robbins LLP related ↔ Aaron Dumas, Jr.
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.